Proxima Ventures

Proxima Ventures is a Shanghai, China-headquartered healthcare-specialist venture capital firm founded in 2015. The firm's mission is to improve the health and lives of people worldwide by investing in emerging global healthcare technologies — with thematic concentration across biotechnology, novel therapeutics, medical devices, diagnostics, clinically significant digital healthcare solutions, advanced data analytics platforms, and innovative business models emerging from China's healthcare system reform. Proxima manages multiple funds denominated in both Chinese RMB and US dollars and is stage-agnostic within healthcare — deploying capital across angel, early, and growth-stage rounds with follow-on support through downstream financing. The firm is led by Founding Partner and Managing Partner George Li and Partner Haolin Sung. As of late 2025, Proxima Ventures has made approximately 105 disclosed investments, with consistent recent activity across surgical devices, drug discovery, and digital health. Notable recent deals include Shengxin Medical (surgical devices, most recent disclosed investment, November 2025), BridGene Biosciences (Series B-II, October 2025), Rapafusyn Pharmaceuticals (participated in a $28 million Series A in June 2024 — non-degrading molecular glue drug discovery), and Bioelectronica Corporation (co-invested with Co-win Ventures to accelerate pharmaceutical discovery and development). Proxima's team brings deep operating and investing experience in the life sciences industry alongside an extensive clinical and industrial network inside China. This local knowledge is a meaningful asset: China's healthcare system reform, aging population, and accelerating biotech research ecosystem create deal-flow dynamics and regulatory pathways that require genuine on-the-ground expertise to navigate. The firm's RMB-and-USD dual-currency structure allows it to invest efficiently across both domestic Chinese companies and internationally-oriented biotechs with China market ambitions.